Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=29493093
&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215
Highlights of the 2017 European AIDS Clinical Society (EACS) Guidelines for the
treatment of adult HIV-positive persons version 9 0
#MMPMID29493093
Ryom L
; Boesecke C
; Bracchi M
; Ambrosioni J
; Pozniak A
; Arribas J
; Behrens G
; Mallon P
; Puoti M
; Rauch A
; Miro JM
; Kirk O
; Marzolini C
; Lundgren JD
; Battegay M
HIV Med
2018[May]; 19
(5
): 309-315
PMID29493093
show ga
BACKGROUND: The European AIDS Clinical Society (EACS) Guidelines have since 2005
provided multidisciplinary recommendations for the care of HIV-positive persons
in geographically diverse areas. GUIDELINE HIGHLIGHTS: Major revisions have been
made in all sections of the 2017 Guidelines: antiretroviral treatment (ART),
comorbidities, coinfections and opportunistic diseases. Newly added are also a
summary of the main changes made, and direct video links to the EACS online
course on HIV Management. Recommendations on the clinical situations in which
tenofovir alafenamide may be considered over tenofovir disoproxil fumarate are
provided, and recommendations on which antiretrovirals can be used safely during
pregnancy have been revised. Renal and bone toxicity and hepatitis C virus (HCV)
treatment have been added as potential reasons for ART switches in fully
virologically suppressed individuals, and dolutegravir/rilpivirine has been
included as a treatment option. In contrast, dolutegravir monotherapy is not
recommended. New recommendations on non-alcoholic fatty liver disease, chronic
lung disease, solid organ transplantation, and prescribing in elderly are
included, and human papilloma virus (HPV) vaccination recommendations have been
expanded. All drug-drug interaction tables have been updated and new tables are
included. Treatment options for direct-acting antivirals (DAAs) have been updated
and include the latest combinations of sofosbuvir/velpatasvir/voxilaprevir and
glecaprevir/pibrentasvir. Recommendations on management of DAA failure and acute
HCV infection have been expanded. For treatment of tuberculosis (TB), it is
underlined that intermittent treatment is contraindicated, and for resistant TB
new data suggest that using a three-drug combination may be as effective as a
five-drug regimen, and may reduce treatment duration from 18-24 to 6-10 months.
CONCLUSIONS: Version 9.0 of the EACS Guidelines provides a holistic approach to
HIV care and is translated into the six most commonly spoken languages.
free
free
free
